Faculty introduction and disclosures

Introductory content and review of H. pylori infection  Epidemiology  Diagnostic methods  Complications and health burden

Management of H. pylori infection  Factors impacting therapeutic decision-making The literature-supported options guideline-recommended roles of treatment options  Bismuth quadruple therapy  Clarithromycin-based therapy and its variations  Levofloxacin-based therapy  Review of newer regimens and their roles  Approaches to salvage therapy  Post-treatment testing to confirm infection eradication for successful management of H. pylori  Challenges to successful H. pylori treatment and optimal outcomes: antibiotic resistance, tolerability, treatment duration, and appropriate follow-up  Best practice: putting it all together  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall challenges in the management of H. pylori infection, including testing, treatment, and healthcare burden.
• Describe the ways in which prior antibiotic exposures and antimicrobial resistance impact H. pylori treatment decision-making.
• Identify the pharmacotherapeutic treatment options for H. pylori infection.
• Formulate a treatment plan for a patient with H. pylori infection.

ACCME Activity #202546863

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Anisa Shaker, MD, Associate Professor of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of USC, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Phathom Pharmaceuticals.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version